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A ligand-based system for receptor-
specific delivery of proteins
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Balint Doleschall1, Fernanda de castro Reis1, Linda nocchi1, Cora H. chadick1, 
Luc Reymond2,3, Ivan R. corrêa Jr.4, Kai Johnsson5, Jamie A. Hackett1 & Paul A. Heppenstall1*
Gene delivery using vector or viral-based methods is often limited by technical and safety barriers. 
A promising alternative that circumvents these shortcomings is the direct delivery of proteins into 
cells. Here we introduce a non-viral, ligand-mediated protein delivery system capable of selectively 
targeting primary skin cells in-vivo. Using orthologous self-labelling tags and chemical cross-linkers, 
we conjugate large proteins to ligands that bind their natural receptors on the surface of keratinocytes. 
Targeted CRE-mediated recombination was achieved by delivery of ligand cross-linked CRE protein to 
the skin of transgenic reporter mice, but was absent in mice lacking the ligand’s cell surface receptor. 
We further show that ligands mediate the intracellular delivery of Cas9 allowing for CRISPR-mediated 
gene editing in the skin more efficiently than adeno-associated viral gene delivery. Thus, a ligand-based 
system enables the effective and receptor-specific delivery of large proteins and may be applied to the 
treatment of skin-related genetic diseases.
Intracellular delivery of biologically active cargoes is of fundamental importance for multiple research and clin-
ical applications. Direct access to the interior of a cell enables, among others, gene editing1,2, modulation of gene 
expression3 and ex-vivo cell therapies4. Realization of these applications is commonly achieved by delivery of 
exogenous nucleic acids or virus-based methods. Despite their broad use, these techniques often present tech-
nical and safety drawbacks such as immunogenicity, risk of permanent integration (genotoxicity) or off-target 
effects. Moreover, viral vectors have limitations in cargo size narrowing their efficacy. In contrast, protein-based 
approaches substantially reduce those risks, and indeed, over the last three decades, proteins have emerged as a 
new class of therapeutic drugs5–7.
There are several obstacles for direct protein delivery into cells including cellular internalization and the 
ability to reach the cytosol of the cell. To overcome these hurdles, proteins can be delivered via physical (e.g. 
electroporation, microinjection) and biochemical modalities (e.g. pore-forming agents, cell-penetrating pep-
tides)8. However, those methodologies are often restricted to in-vitro applications or can expose the cell to harsh 
treatments that are toxic. Most importantly, they lack selectivity, a critical parameter for specific targeting of 
cells in complex in-vivo environments, especially in clinical applications. Thus, efficient intracellular delivery of 
functional, intact proteins remains a major technological challenge. A valid alternative for instance, is the use 
of molecular Trojan horse technology where receptor-specific monoclonal antibodies are genetically fused to 
biologics for their selective delivery across the brain blood barrier9,10. Two recent studies have also employed a 
ligand-mediated approach for targeted delivery of large cargoes in-vitro. In a first study Chen and collaborators 
conjugated the human transferrin protein to a zinc-finger nuclease to perform cell-type specific genome editing11. 
Similarly, an engineered version of Cas9 fused to the asialoglycoprotein ligand was selectively delivered in liver 
cells through a receptor-mediated internalization mechanism12. Both works highlighted the many advantages of 
using a ligand-based platform including good selectivity, low cell-toxicity and precise temporal control. However, 
the employment of these systems in-vivo represents the next challenge.
In this study, we aimed to develop a receptor-specific targeting tool using the skin as a model for ex-vivo and 
in-vivo delivery. Skin is the largest organ of the body and plays both a protective and sensory role in interacting 
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with the external environment. Keratinocytes are the major cell type of this organ, and these cells constantly cycle 
to maintain a functional barrier that protects against invading pathogens such as virus or bacteria. Despite the 
accessibility of the skin, keratinocytes are not amenable to most of the standard delivery methodologies, and they 
have proven to be extremely difficult to target with external molecules13. This in turn limits the development of 
strategies for effective therapies of skin-related diseases. In this light, a ligand-based system could represent a key 
technology to gain access to keratinocytes, enabling novel therapeutic applications in the skin.
We previously described a protein based tool for the delivery of a small molecule photosensitizer to the skin, 
along with a light-mediated control of itch and inflammatory skin disease14. This approach was based upon a 
SNAP-tagged engineered version of the cytokine interleukin-31 (IL-31K138ASNAP), that binds to its receptors 
(IL31RA and OSMR) on keratinocytes, but does not provoke cellular signaling. Here, we have asked whether an 
analogous approach might also be used to deliver large, biologically active proteins to keratinocytes. We found 
that IL-31K138ASNAP is translocated to the nucleus of primary murine keratinocytes upon internalization. We 
further identified a second non-signaling ligand (Nerve Growth Factor R121W; NGFR121WSNAP)15 that also binds 
to keratinocytes and is translocated to the nucleus. Together, these observations suggested that conjugation of 
cargoes to IL-31K138ASNAP or NGFR121WSNAP might allow for their intracellular uptake in primary keratinocytes. 
To test this, we generated recombinant CLIP-tagged CRE recombinase and Cas9 nuclease, to enable their chem-
ical crosslinking to SNAP-tagged ligands using bifunctional benzylcytosine (BC) and benzylguanine (BG) sub-
strates16. We demonstrate that cross-linked complexes are selectively delivered into primary keratinocytes both 
in-vitro and in-vivo and can achieve cell-type specific gene editing including homology-directed repair in-vivo.
Results
Nuclear translocation of IL-31K138ASnAp and nGfR121WSNAP in keratinocytes. A critical step 
for the delivery of functional proteins is the ability to gain access to the interior of a cell upon uptake. While 
performing live imaging experiments to characterize the binding and internalization of BG-Surface549 (BG549) 
labelled IL-31K138ASNAP to keratinocytes (Fig. S1A), we observed a robust translocation of the ligand to the 
nucleus of cells over the course of a 2 hour incubation (Fig. 1a–c). Similarly, we investigated whether a second 
ligand (NGFR121WSNAP)15 was able to bind to keratinocytes through recognition of its natural receptors which 
are also highly expressed in this type of cells17. BG-Surface549 labelled NGFR121WSNAP (Fig. S1B) was applied to 
primary mouse keratinocytes at increasing concentrations. As expected and similar to previous reported stud-
ies18, we also detected a strong fluorescence in the cell nucleus upon prolonged incubation (2 hours) with the 
NGF-probe (Fig. 1a,b,d). In contrast, minimal cellular internalization was observed when cells were treated with 
labelled SNAP-tag alone (in the absence of ligand) or with BG-Surface549 (Figs. 1b and S1C,D). Cellular inter-
nalization of SNAP-tagged ligands of interest was further confirmed by Western Blot analysis (Fig. S1G). Thus, 
IL-31K138ASNAP and NGFR121WSNAP ligands bind to primary keratinocytes and are translocated to the nucleus, 
enabling intracellular access.
Chemical cross-linking of SNAP-ligands to CLIP-Cre. We reasoned that the rapid nuclear transloca-
tion of SNAP-ligands might be exploited to allow for targeted delivery of biologically active protein cargoes in 
primary keratinocytes. To this end, we first attempted to generate fusion proteins of ligand and CRE recombinase 
but were unable to recover active proteins at sufficient yields. We therefore asked whether selective cross-linking 
(S-CROSS)16 could be employed to bind molecules of interest. S-CROSS is based on self-labelling tags (SNAP and 
CLIP), which covalently bind synthetic probes and has been previously used to detect protein-protein interactions 
in living cells16,19. Recombinant CRE recombinase fused to a N-terminal CLIP-tag (CLIP-Cre) was produced in E. 
Coli and CLIP activity was confirmed by selective labelling with a BC-derivative fluorophore (BC488) (Fig. S1E). 
S-CROSS was next assessed in-vitro by mixing molar equivalents of CLIP-Cre with SNAP-ligands together with 
cross-linker molecules carrying both BG and BC moieties on their ends, as schematically shown in Fig. 1e. We 
screened several cross-linker candidates in order to identify the synthetic probe that allowed the highest yield of 
S-CROSS (Table S1 and Fig. S1F). We determined that long linkers (>25 Å; linker #2, #3, #5, #6; Table S1) were 
more effective for S-CROSS, most likely because they reduce steric hindrance thus allowing the reactive groups 
(BG and BC) to have better access to the SNAP and CLIP tags. In particular, linker #520 (Table S1) was found to 
display the highest rate of S-CROSS. Finally, optimization of the cross-linking process was achieved through a 
two-step reaction (Fig. 1f): CLIP-tagged cargo was firstly saturated with the cross-linker (linker #5) and, after 
elimination of the unbound compound, SNAP-ligands were added to the reaction mix. Up to 60% cross-linking 
was obtained with no excess of free SNAP-ligand present in the final product (Fig. 1g,h).
Ligand-mediated selective delivery of CLIP-Cre in-vitro. To assess whether targeted delivery of 
cross-linked CLIP-Cre to ligands of interest was functional, we applied S-CROSS complexes to primary adult 
murine keratinocytes cultured from Rosa26LSL-ChR2-YFP reporter mice, in which yellow fluorescent protein 
(YFP) expression is induced upon CRE-mediated recombination. CLIP-Cre, cross-linked in-vitro to either 
IL-31K138ASNAP (IL-31SNAP::CLIPCRE; linker #5, Table S1) or NGFR121WSNAP (NGFSNAP::CLIPCRE; linker #5, 
Table S1) was applied to keratinocytes and after 5 days YFP expression was assessed (Fig. 2a). Upon a single 
in-vitro treatment we observed 26.5% ± 4.9 expression of reporter YFP for IL-31SNAP::CLIPCRE complex and 
20.0% ± 2.6 when cells were treated with NGFSNAP::CLIPCRE S-CROSS (Fig. 2b). Of note, the percentage of tar-
geted cells was similar to the number of keratinocytes labelled with free SNAP-tagged ligands (Fig. 1c; 1 μM 
condition). Importantly, negligible YFP expression (0–3%) was detected upon incubation with a cross-linked 
binary complex lacking ligands of interest (SNAP::CLIP-CRE; linker #5, Table S1) or when CLIP-Cre alone was 
applied to keratinocytes (Fig. 2b) suggesting that S-CROSS internalization is primarily driven by ligands. To 
confirm the selectivity of the system, we used a Rosa26LSL-ChR2-YFP reporter mouse model lacking the Interleukin 31 
receptor alpha subunit (IL31RA−/−)14. Rosa26LSL-ChR2-YFP mice were crossed with IL31RA−/− mice and primary 
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Figure 1. Binding of SNAP-tagged ligands to keratinocytes and selective cross-linking to CLIP-tagged 
enzymes. (a) Schematic representation of one keratinocyte expressing the receptors of interest and the ligands 
used. (b) Quantification of labelled IL-31K138ASNAP-BG549 (c), NGFR121WSNAP-BG549 (d) and SNAP-BG549 
(green bars) binding to primary keratinocytes. Nuclear localization was observed after 2 hours treatment. The 
nuclei were stained with Hoechst. Scale bars, 20 μm. The insets represent corresponding brightfield images. 
(e) 3D structures showing selective cross-linking of SNAP-tagged ligands (NGF-SNAP) and CLIP-tagged 
proteins (CLIP-Cre) through a BG-TMR-PEG-BC linker (PDB ID codes: 1BET, 1KBU, 3KZY). (f) Schematic 
representation of S-CROSS optimized chemical reaction. (g) Representative Coomassie gel showing cross-
linking complexes (red asterisks). First lane (#1) is IL-31SNAP::CLIPCRE, second lane (#2) is NGFSNAP::CLIPCRE and 
third lane (#3) is SNAP::CLIP-CRE. (h) Quantification of cross-linking from Coomassie gel (g).
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keratinocytes were cultured. S-CROSS (IL-31SNAP::CLIPCRE or NGFSNAP::CLIPCRE; linker #5, Table S1) was applied 
to keratinocytes and YFP expression was assessed. Strikingly, no YFP activation was detected on cells treated with 
the cross-linking complex carrying the IL-31 ligand, while NGF S-CROSS displayed a similar YFP activation as 
for wild-type Rosa26LSL-ChR2-YFP keratinocytes (Fig. 2c). Thus, SNAP-tagged ligands mediate selective intracellular 
delivery of CLIP-Cre in-vitro.
Ligand-mediated selective delivery of CLIP-Cre in-vivo. We next investigated whether 
IL-31K138ASNAP or NGFR121WSNAP ligands can drive intracellular delivery of CLIP-Cre in-vivo in mice. S-CROSS 
reactions (IL-31SNAP::CLIPCRE or NGFSNAP::CLIPCRE; linker #5, Table S1) were injected subcutaneously into the ear 
of Rosa26LSL-ChR2-YFP reporter mice and after 3 weeks, YFP expression was assessed by confocal microscopy on 
whole mount samples (Fig. 3a). Upon a single treatment, broad YFP expression was detected in keratinocytes 
of both mice injected with IL-31SNAP::CLIPCRE and NGFSNAP::CLIPCRE (Fig. 3b left panel and c). No YFP signal 
was observed after injection with SNAP::CLIP-CRE complex or CLIP-Cre alone (Fig. 3b left panel and C and 
Fig. S2A). Moreover, subcutaneous injection of a recombinant cell-permeant peptide fusion CRE-recombinase 
protein21,22 (TAT-Cre) led to a non-cell specific YFP expression and displayed lower efficiency compared with 
ligand-driven delivery (Fig. 3b left panel and c). We further validated cell-type specific delivery by injecting 
S-CROSS into the ear of double transgenic IL31RA knockout/reporter mice (Rosa26LSL-ChR2-YFP::IL31RA−/−). No 
YFP signal was observed upon injection with IL-31SNAP::CLIPCRE complex whereas reporter activation was 
maintained for NGF-mediated delivery of CLIP-Cre (Fig. 3B right panel and d). These results demonstrate that 
ligand-mediated delivery is functional and selective also in-vivo.
Chemical cross-linking of SNAP-ligands to CLIP-Cas9. We next asked whether SNAP-ligand 
cross-linking can also be used to deliver Cas9 nuclease intracellularly. Similar to CLIP-Cre, a recombinant ver-
sion of Cas9 nuclease fused to an N-terminal CLIP-tag (CLIP-Cas9) was produced in E. Coli. Efficient labelling 
with a BC derivative fluorophore (BCTMR) was observed indicating that the CLIP-tag was active (Fig. S3A). The 
functionality of CLIP-Cas9 was then assessed at the in-vitro level and in-cell, by monitoring nuclease activity at 
the mouse Atat1 locus. In an in-vitro digestion assay (IDA)23 using Atat1 PCR product and chemically synthesized 
dual RNAs (Atat1 crRNA and trRNA) we observed efficient cleavage of the PCR product (Fig. S3E). We tested 
recombinant CLIP-Cas9 nuclease activity in-cell by direct electroporation of preassembled CLIP-Cas9::sgRNA 
(Atat1 crRNA and trRNA) ribonucleoprotein (RNP) complexes in primary keratinocytes isolated from C57BL/6J 
WT adult mice (Fig. 4a). Gene editing was observed by tracking of indels by decomposition analysis (TIDE)24 of 
the PCR amplicons from the Atat1 genomic locus and confirmed by T7 endonuclease 1 (T7E1) assay (Figs. 4b 
and S3B). Of note, CLIP-Cas9 gene editing efficiency (45.2%) was comparable to native Cas9 activity (60.2%) 
when the latter was electroporated together with sgRNA (Cas9::sgRNA) in keratinocytes (Fig. S3C). We further 
Figure 2. Ligand-mediated delivery of cross-linked CLIP-Cre. (a) Schematic of in-vitro keratinocytes treatment 
with cross-linked complexes. (b) Images and quantification of YFP positive primary keratinocytes (% of cells) 
from Rosa26LSL-ChR2-YFP mice 5 days after treatment with 2 μM of cross-linked complexes or CLIP-Cre alone. 
(c) Representative images and quantification of YFP positive primary keratinocytes from double transgenic 
Rosa26LSL-ChR2-YFP::IL31RA−/− mice 5 days after treatment with 2 μM of cross-linked complexes or CLIP-Cre 
alone. Scale bars, 20 μm. The insets represent corresponding brightfield images. The horizontal lines mark 
the geometric mean and the error bars mark the standard error. Representative data from n = 3 independent 
experiments.
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assessed selective cross-linking of ligands with recombinant CLIP-Cas9. Similar to CLIP-Cre S-CROSS, we 
obtained up to 35% of cross-linked CLIP-Cas9 to IL-31K138ASNAP (IL-31SNAP::CLIPCas9, linker #5, Table S1) and 
about 55% to NGFR121WSNAP (NGFSNAP::CLIPCas9, linker #5, Table S1) (Fig. S3D). Thus, validation assays showed 
that CLIP-Cas9 was functional and efficiently conjugated to ligands of interest.
Internalization of ligand cross-linked CLIP-Cas9 complexes. To determine whether Cas9 
S-CROSS could be internalized in keratinocytes, CLIP-Cas9 was cross-linked in-vitro to either IL-31K138ASNAP 
Figure 3. Selective delivery of cross-linked CLIP-Cre in-vivo. (a) Schematic of in-vivo treatment with cross-
linked complexes. (b) Quantification (number of cells per mm2) of YFP positive keratinocytes from Rosa26LSL-
ChR2-YFP mice (c) and from double transgenic Rosa26LSL-ChR2-YFP::IL31RA−/− mice (d) 3 weeks after subcutaneous 
injection with 5 μM (0.85 mg/kg) of cross-linked complexes or TAT-Cre. The nuclei were stained with DAPI. 
Scale bars, 40 μm. The insets show the zoom of representative areas. Green arrows indicate YFP+ keratinocytes. 
Red arrows indicate non-selective YFP expression. The horizontal lines mark the geometric mean and the error 
bars mark the standard error. Data from n = 3 independent experiments.
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(IL-31SNAP::CLIPCas9) or NGFR121WSNAP (NGFSNAP::CLIPCas9) using a linker carrying a TMR fluorophore (linker 
#625; Table S1) to monitor internalization (Fig. S4A). IL-31SNAP::CLIPCas9 or NGFSNAP::CLIPCas9 (linker #6) were 
applied to cultured murine WT primary keratinocytes, and after 2 hours of incubation, S-CROSS uptake was 
assessed using live cell imaging. Red fluorescence was observed inside the cells, mostly localized in the nuclei 
suggesting that the protein complex was internalized (Fig. 4c,d, condition #1). We next investigated whether 
ribonucleoprotein complexes (IL-31SNAP::CLIPCas9 or NGFSNAP::CLIPCas9 bound to sgRNA targeting Atat1 gene) 
were taken up by primary keratinocytes. Ligand cross-linked CLIP-Cas9 complexes were incubated in-vitro with 
sgRNA (IL-31SNAP::CLIPCas9::sgRNA or NGFSNAP::CLIPCas9::sgRNA), applied to cultured cells, and internalization 
was assessed after 2 hours. Compared to ligand-Cas9 complexes alone, an apparent reduction of the fluorescent 
intracellular signal was observed for both complexes upon addition of sgRNA (Fig. 4c,d, condition #2). Decreased 
S-CROSS internalization in the presence of sgRNA was further confirmed by Western blotting analysis (Fig. S4B). 
As expected, and similar to a previous study performed in primary cells12, no gene editing at the Atat1 locus 
was detected in keratinocytes using ligand-Cas9 RNP complexes (Fig. S4F). Taken together, these data indicate 
that ligands can mediate cell-specific delivery of Cas9 protein, however the presence of sgRNA interferes with 
RNP internalization mechanisms. To address this issue, we selected two candidate peptides that have previously 
been described to promote internalization, protamine and ppTG21, and investigated whether RNP delivery was 
improved in their presence. Protamine is a small positively charged peptide which binds with high affinity to 
Figure 4. CLIP-Cas9 activity and internalization in keratinocytes. (a) Schematic of CLIP-Cas9::sgRNA 
electroporation strategy. (b) Indel spectrum determined by TIDE of primary keratinocytes electroporated with 
CLIP-Cas9::sgRNA targeting the Atat1 gene. The inset show T7 endonuclease 1 assay performed on genomic 
DNA from electroporated keratinocytes. t.e. = total efficiency. (c) Quantification (% cells) and representative 
images (d) of TMR positive cells upon 2 hours treatment with 2 μM of ligand cross-linked Cas9 (#1 no sgRNA; 
#2 with sgRNA; #3 with sgRNA+ protamine; #4 with sgRNA + ppTG21). Nuclei were stained with Hoechst. 
Scale bars, 20 μm. The horizontal lines mark the geometric mean and the error bars mark the standard error.
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nucleic acids and has been previously employed for small and long RNA delivery26,27 (Fig. S4C). ppTG21 is an 
endosomolytic peptide demonstrated to enhance endosomal escape of Cas9 RNP complexes whilst maintaining 
selectivity12. Preassembled IL-31SNAP::CLIPCas9::sgRNA or NGFSNAP::CLIPCas9::sgRNA were incubated in-vitro with 
an excess of protamine and then applied to cultured cells. After 2 hours of treatment, an increase of fluorescent 
signal was observed in the nuclei of live cells suggesting that co-incubation with protamine can favour cellular 
internalization of RNP complexes (Fig. 4c,d, condition #3). We further examined S-CROSS::sgRNA complex 
internalization in the presence of ppTG21. Preassembled IL-31SNAP::CLIPCas9::sgRNA or NGFSNAP::CLIPCas9::sgRNA 
were co-incubated in-vitro with 30 molar equivalent of ppTG21 peptide, applied to cells and imaged 2 hours later. 
In contrast to protamine, ppTG21 did not improve RNP internalization (Fig. 4c,d, condition #4). Negligible inter-
nalization was also observed in control conditions when TMR-labelled CLIP-Cas9 (CLIP-Cas9 + linker #6) was 
applied to cells in the absence of ligand (with or without sgRNA, Protamine, or ppTG21 (Fig. S4D,E, conditions 
#1–4). Finally, we assessed in-cell gene editing at the Atat1 locus using ligand-Cas9 complexes delivered under the 
conditions described above. Unexpectedly, while we found that protamine facilitates internalization, sequencing 
data indicated that RNP complexes were no longer functional (Fig. S4F). We thus hypothesized that protamine 
sequesters or blocks the interaction of sgRNA with Cas9 or its target.
In-cell gene editing using ligand-mediated delivery of CLIP-Cas9. Based on the above observation, 
we reasoned that the sgRNA may have to be provided independently to achieve in-cell gene editing upon ligand 
mediated delivery of Cas9. To test this hypothesis, we electroporated a plasmid encoding Blue Fluorescent Protein 
(BFP) as a transfection marker, and a U6 promoter driven sgRNA targeting the Atat1 locus (U6-sgRNA) into pri-
mary keratinocytes. After 36 hours, and upon expression of BFP in 12.2% ± 0.4 of cells (Fig. S5A,B), ligand con-
jugated CLIP-Cas9 was applied to keratinocytes. We tested both IL-31K138ASNAP and NGFR121WSNAP mediated 
delivery, three different cross-linkers (linker #3, #5 and #6, Table S1), and the endosomolytic peptide ppTG21. 
48–72 hours after treatment, BFP positive keratinocytes were sorted by flow cytometry and genomic DNA was 
extracted to assess editing at the Atat1 locus (Fig. 5a). Gene editing was observed with comparable efficiency 
for both ligands at significantly greater levels than control conditions (6.2% ± 0.5 indels for IL-31SNAP::CLIPCas9; 
6.6% ± 2.4 indels for NGFSNAP::CLIPCas9; 1.9% ± 0.2 indels for control conditions) (Figs. 5b and S5E). We also 
observed enhanced internalization of ligand cross-linked Cas9 (without sgRNA) in the presence of ppTG21 
(Fig. S5C,D), and this was also evident as a substantial improvement in gene editing frequency for linker #5 
(19.8% indels for NGFSNAP::CLIPCas9, Figs. 5b and S5E). Thus, supplying sgRNA via a separate route to the 
ligand-delivered Cas9, allows for gene editing in primary keratinocytes.
Ligand-mediated delivery of CLIP-Cas9 allows for homology directed repair. As a further 
readout for gene editing efficiency, in particular for in-vivo experiments, we next investigated whether 
ligand-mediated delivery of CLIP-Cas9 could also be employed for genomic knock-in of a fluorescent reporter 
through homology-directed repair (HDR)28. To achieve this, we used a previously described strategy employing 
an adeno-associated virus (AAV) containing a U6-sgRNA targeting the mouse ß-Actin gene and a donor template 
encoding for the monomeric Green Fluorescent Protein (mEGFP) with homology arms for targeted insertion at 
the N-terminus of ß-Actin29 (Fig. 5c). We assessed the approach in murine neuroblastoma Neuro-2a (N2a) cells30 
overexpressing NGF receptors and shown to be bound by NGFR121WSNAP (Fig. S6A). Cells were infected with an 
AAV serotype 1/2 vector containing ß-Actin sgRNA and donor template (AAV1/2::HDR), and 8–24 hours later, 
treated with NGF cross-linked CLIP-Cas9 (NGFSNAP::CLIPCas9) (Fig. 5c). Again, gene-editing efficiency was assessed 
for three different cross-linkers (linker #3, #5 and #6, Table S1) in the presence or absence of the ppTG21 pep-
tide. Remarkably, at 72–96 hours post-treatment we observed mEGFP expression localized to the cytoskeleton in 
cells (Fig. 5d,e). This was present in 8.9% ± 2.1 of cells (Fig. 5f). Cross-linked complex using linker #3 (Table S1) 
displayed the highest efficiency (~15%) while linker #5 and #6 were shown to be less effective (~5–7%) (Fig. 5f). 
Intriguingly, and in agreement with sequencing results (Fig. 5b), co-incubation with ppTG21 led to an increase in 
HDR efficiency for linker #5 but not for other linkers (Fig. 5f). Importantly, no mEGFP signal was detected in cells 
infected only with AAV1/2::HDR (0.1% ± 0.1) or treated with CLIP-Cas9 alone (Figs. 5e,f and S6B).
We next investigated whether ligand-mediated delivery of CLIP-Cas9 allows for HDR in-vivo in the 
skin. IL-31SNAP::CLIPCas9 or NGFSNAP::CLIPCas9 (linker #5, #3, #6) were injected subcutaneously into the ear of 
C57BL/6J WT mice together with the AAV1/2::HDR vector (Fig. 6a). 2–3 weeks post-treatment, we evaluated 
mEGFP-ß-Actin expression by confocal microscopy on whole mount samples (Fig. 6a). We observed clusters of 
mEGFP positive keratinocytes around the injection site (Fig. 6c,d), with linker #3 showing the highest efficiency, 
especially for NGF-mediated delivery (Fig. 6c, green square). HDR was also observed, at lower frequency, in 
samples injected with cross-linked complexes carrying linker #6 (Fig. 6c, red circle), while no HDR event was 
detected for S-CROSS linker #5 (Fig. 6c, black triangle). Finally, we benchmarked the ligand-based system against 
viral delivery of Cas9. AAV1/2::HDR and a second AAV carrying the Cas9 sequence (AAV1/2::Cas9)29 were sub-
cutaneously injected into the ear of WT mice, and skin samples were analyzed by confocal microscopy 2–3 weeks 
later. We detected no mEGFP fluorescence in any skin sample after viral delivery of Cas9 (Fig. 6b), indicating 
that delivery of Cas9 protein through ligand conjugation may offer a more efficient means of targeting the skin.
Discussion
Here we present a method for non-viral receptor-dependent delivery of large cargoes chemically conju-
gated to protein ligands. Based on previous evidence14, we have demonstrated that a non-signalling ligand 
(IL-31K138ASNAP) is translocated to the nucleus of primary keratinocytes upon recognition of its natural het-
erodimeric receptor complex (IL31-RA/OSMR). We have further identified and characterized the ability of a sec-
ond non-signalling ligand (NGFR121WSNAP)15 to target keratinocytes. Upon internalization, NGFR121WSNAP was 
also shown to be translocated to the nucleus of the targeted cells. NGF internalization and its nuclear transport 
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through a receptor-mediated endocytosis mechanism was previously reported to occur in neurons18,31,32. In addi-
tion to providing access to receptor-specific expressing cells, the engineered ligands we used here do not provoke 
pain or scratching behaviour, thus representing a valuable delivery tool for both in-vitro and in-vivo applications.
We exploited these ligands to deliver two different cargo proteins, CRE recombinase and Cas9 nuclease into 
cells. We covalently cross-linked molecules of interest using SNAP and CLIP-tag fusions, together with long 
bio-orthogonal linkers. The main advantage of this approach is its versatility, allowing the mixing of combinations 
Figure 5. Ligand-mediated delivery of cross-linked CLIP-Cas9 in cultured cells. (a) Schematic of plasmid 
electroporation strategy in primary keratinocytes. (b) % of indels detected from DNA sequencing of BFP-
sorted keratinocytes expressing Atat1 U6-sgRNA and treated with: cross-linked complex IL-31SNAP::CLIPCas9 
(3rd column from left), IL-31SNAP::CLIPCas9 + ppTG21 (4th column from left), NGFSNAP::CLIPCas9 (5th column 
from left) and NGFSNAP::CLIPCas9 + ppTG21 peptide (6th column from left). Untreated keratinocytes and 
untreated BFP-sorted keratinocytes are shown in column 1 and 2, respectively. (c) Graphical representation 
of AAV1/2::HDR and N2a cells experimental strategy. (d) Zoom of mEGFP-ß-Actin N2a positive cell. 
(e) Confocal images of AAV1/2::HDR transduced N2a WT cells overexpressing NGF receptors treated with 
NGFSNAP::CLIPCas9 alone (upper frames) or in presence of ppTG21 peptide (lower frames). First images on 
the left show control N2a cells infected only with AAV1/2::HDR. Scale bars, 40 μm. The insets represent 
corresponding brightfield images. (f) Quantification (% cells) of mEGFP positive cells from (e). The horizontal 
black lines mark the geometric mean and the error bars mark the standard error. Black triangles: cross-linking 
complexes carrying linker #5 (Table S1); green squares: cross-linking complexes carrying linker #3 (Table S1); 
red circles: cross-linking complexes carrying linker #6 (Table S1).
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Figure 6. Ligand-mediated delivery of cross-linked CLIP-Cas9 in-vivo. (a) Schematic of subcutaneous 
injection of cross-linked CLIP-Cas9 and AAV1/2::HDR. (b) Confocal images showing control samples injected 
only with AAV1/2::HDR (left frame) or with dual AAV system AAV1/2::HDR + AAV1/2::Cas9 (right frame) 
(c) Confocal images of mEGFP positive keratinocytes 2–3 weeks after subcutaneous injection into the mouse 
ear, with AAV1/2::HDR and CLIP-Cas9 cross-linked to IL-31 (top) or NGF (bottom). The nuclei were stained 
with DAPI. Scale bars, 40 μm. The insets show enlarged representative areas with mEGFP-ß-Actin positive cells. 
Black triangles: cross-linking complexes carrying linker #5 (Table S1); green squares: cross-linking complexes 
carrying linker #3 (Table S1); red circles: cross-linking complexes carrying linker #6 (Table S1). (d) Mosaic 
confocal image (1.07 mm × 1.43 mm) of mEGFP-ß-Actin positive cells from WT mice 2–3 weeks after 
subcutaneous injection with AAV1/2::HDR and NGFSNAP::CLIPCas9 (linker #3). The nuclei were stained with 
DAPI. White dashed circles mark mEGFP positive targeted cell clusters. White arrows indicate mEGFP positive 
cells starting to express mEGFP. Scale bar, 100 μm.
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of “protein building blocks” using a two-step simple chemical reaction and avoiding issues related to the pro-
duction of large fusion proteins. We have identified three different linkers (linker #3, #5, #6) shown to minimize 
steric hindrance effects between cargoes and ligands, thus allowing for high yields of cross-linking complexes. In 
addition to this, selected probes contain functional moieties which enable imaging (TMR, linker #6) and poten-
tially promote the uptake and the endosomal escape of the protein complexes (biotin, linker #3 and #5; TMR, 
linker #6)33,34.
Both IL-31 and NGF ligands displayed efficient delivery of biologics into studied cells which was lost in the 
absence of receptors, thus demonstrating that the system is receptor-specific. Importantly, they enabled access to 
keratinocytes, which constitute the major cellular component of the skin and the first barrier from the external 
environment. Keratinocytes have been shown to be highly resistant to viral infection or to standard established 
delivery methods (e.g. lipid-based reagents), making them a challenging target. To that end, our system could be 
a viable tool to target the skin. However, since other cell types in the skin are known to express IL-31 and NGF 
receptors17,35–37, in future studies it will be important to investigate the delivery of cargoes to these cells together 
with the pharmacodynamics of the system in the skin.
Many keratinocyte associated genetic disorders have been described38–40 with no effective therapies available 
on the market. In this light, the technology we describe here could represent a promising platform for treating 
those diseases. Furthermore, the direct delivery of Cas9 as a protein has the advantage of minimizing risks of 
potential integration into genomic DNA and prolonged exposure to the nuclease, that are associated with other 
delivery methods (viral vectors or plasmid-based technologies), making it a safer alternative. Future improve-
ments will focus on increasing delivery efficiency and on expanding the system to other types of cargoes (for 
example siRNA and therapeutic proteins). We also expect our strategy could be expanded to distinct biologics 
(ligands, antibodies or small molecules) that bind to specific cell-surface receptors, thus allowing for selective 
targeting of many other cellular populations and offering new options to current methodologies.
Methods
Animals. Wild type C57BL/6J, Rosa26LSL-ChR2-YFP and Rosa26LSL-ChR2-YFP::IL31RA−/− mice were used at age of 
7–15 weeks for primary keratinocyte culture. All mice were bred and maintained at the EMBL Neurobiology and 
Epigenetic Unit, Rome, in accordance with Italian legislation (Art. 9, 27. Jan 1992, no. 116) under license from 
the Italian Ministry of Health, and in compliance with the ARRIVE guidelines. Experimental protocols were 
approved by the EMBL Rome Ethics Committee and the Italian Ministry of Health.
Production of recombinant SNAP and CLIP proteins. IL-31K138ASNAP, NGFR121WSNAP and the 
SNAP-tag were produced as previously described14,15,41. cDNAs for CRE recombinase or Cas9 endonucle-
ase together with a CLIP tag were cloned into a pETM-11 vector after a SenP2 cleavage site and expressed 
in E. Coli as fusion protein, carrying a His6-tag-SUMO at the N-terminus. His6-SUMO-CLIP-Cre and 
His6-SUMO-CLIP-Cas9 constructs were recovered from cell lysate with Ni-NTA resin (Qiagen, #30210) and 
eluted with 250 mM imidazole. An overnight (O/N) digestion with His-tagged SenP2 protease was performed at 
4 °C in order to remove the SUMO tag-protein. Excess of imidazole was removed from solution through dialysis. 
Digested products were incubated again with Ni-NTA resin at room temperature (RT) for 1 hr. The flow-through 
containing only the protein of interest was collected. Further purification was performed with Ion Exchange 
chromatography in a HiTrapQ HP column (GE Healthcare) and finally with size exclusion chromatography in 
a Superdex 75 26/60 column (GE Healthcare). The protein-containing fractions were pooled and dialysed O/N 
against Phosphate-buffered saline (PBS), 1 mM DTT, 5% glycerol. Dialysed proteins were then concentrated 
(Amicon Ultra 10 kDa, Merck-Millipore), aliquoted, snap-frozen and stored at −80 °C.
Primary keratinocyte culture. Primary keratinocytes were isolated from adult WT C57BL/6J, 
Rosa26LSL-ChR2-YFP and Rosa26LSL-ChR2-YFP::IL31RA−/− mice as previously described42,43. Briefly, mice were sacrificed 
using CO2 and skins from tails were dissected and digested O/N in a solution of dispase II at 4 mg/mL (Sigma # 
D4693) dissolved in defined Keratinocyte-Serum Free Media (1X) (KSFM; Gibco #10744-019) containing 1% 
penicillin/streptomycin antibiotic and 1 mL of supplied growth supplements. The next day, the epidermis was sep-
arated from the dermis and further digested for 15 minutes at RT in a small amount of TrypLE Express solution 
(Gibco # 12604013), to allow gentle dissociation of primary keratinocytes from the epidermal sheet. Cells were 
filtered through 100 μm cell strainers (Falcon), centrifuged (4 °C, 1200 RPM, 10 minutes), and plated on μ-Dish 
35 mm ibidiTreat dishes (Ibidi) or 96-well plates coated with rat-tail collagen I coating solution (Sigma # 122-20). 
Cells were kept in KSFM in a humidified 37 °C cell incubator with 7% CO2 and media was changed every day.
In-vitro labelling. For keratinocyte labelling, IL-31K138ASNAP, NGFR121WSNAP or SNAP were coupled with 
an excess of BG-Surface549 at a 1:1.5 molar ratio (NEB # S9112) for 2 hours at 37 °C in PBS (pH 7.4) or CIB 
buffer (NaCl 140 mM; KCl 4 mM; CaCl2 2 mM; MgCl2 1 mM; NaOH 4.55 mM; Glucose 5 mM; HEPES 10 mM; 
pH 7.4). The coupling reaction was passed through a PD MiniTrap G-25 column (GE Healthcare #28-9180-07) 
to remove the excess of unbound BG. Cells from wild type mice were incubated with the coupling reaction 
for 2 hours at 37 °C, then washed 3 times in PBS. For N2a cell labelling, NGFR121WSNAP was coupled with an 
excess of BG-Surface549 at a 1:1.5 molar ratio for 2 hours at 37 °C in CIB buffer. The coupling reaction was passed 
through a PD MiniTrap G-25 column to remove the excess of unbound BG. N2a cells were incubated with 
NGFR121WSNAP-BG549 for 1–2 hours at 37 °C, then washed 3 times in PBS. 1 µg/ml Hoechst was used for nuclear 
staining. All images were acquired with a Leica SP5 confocal microscope. For each sample, at least 80 images (for 
a thickness of at least 40 µm) were acquired and then stacked together with maximum intensity using ImageJ. 
Positive cells were clearly distinguished from the background and were counted using the multi-point tool.
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Selective cross-linking reaction (S-CROSS). CLIP-Cre or CLIP-Cas9 were coupled to cross-linkers at 
a molar ratio of 1:1.5 (CLIP-protein:linker) for 2 hours at 37 °C in PBS (pH 7.4) in the presence of 1 mM DTT. 
The reaction was then passed through a PD MiniTrap G-25 column to remove the excess of unbound linker and 
DTT, and concentrated (Amicon Ultra 10 kDa or 100 kDa, Merck-Millipore). Concentration of CLIP protein 
bound to the cross-linker was assessed using a NANODROP ND-8000 or by quantitative densitometry analysis 
of SDS-PAGE with ImageJ. The complex was then reacted with SNAP-ligands (IL-31K138ASNAP, NGFR121WSNAP 
or SNAP) overnight at room temperature in agitation at a 1:0.8 ratio (CLIP-protein-linker:SNAP-ligand) to mini-
mize the presence of free ligand. Final product was analysed by SDS-PAGE. SNAP-capture magnetic beads (NEB 
#S9145S) were used to remove excess of free-ligand when this was present at the end of the process.
In-vitro primary keratinocyte treatment with CLIP-Cre S-CROSS. Cross-linked complexes or 
CLIP-Cre alone were diluted in-vitro in keratinocytes serum free media to the desired concentration (2 μM) 
in a final volume of 100 μl. 36–48 hr after plating, adult primary keratinocytes were co-incubated with 100 μl 
of S-CROSS overnight in a humidified 37 °C cell incubator with 7% CO2. For TAT-Cre treatment, 1 μl (~10 
unit = ~2.3 μM) of TAT-Cre (Merck-Millipore #SCR508) was diluted in-vitro in 100 μl of KSFM and successively 
co-incubated with cultured primary keratinocytes O/N in a humidified 37 °C cell incubator with 7% CO2. The day 
after, cells were washed 3 times with PBS-Heparin (1 mg/ml solution). Media was changed every day. On the fifth 
day after treatment, cells were imaged using a Nikon Eclipse Ti-S inverted microscope or a Leica SP5 confocal 
microscope. All images were analysed with ImageJ. All in-vitro assays were carried out in 96-well plates.
In-vivo treatment with CLIP-Cre S-CROSS. Cross-linked complexes were diluted in-vitro in PBS to the 
desired concentration (5 μM; 0.85 mg/kg) in a final volume of 30 μl and subcutaneously injected into the ear of the 
mice. Samples were injected at the midpoint of the ear, but diffusion of the solution was observed over the whole 
ear after injection.
For TAT-Cre treatment, 2 μl (~20 unit = ~5.6 μM) of TAT-Cre were diluted in-vitro in a final volume of 45 μl 
of PBS and subcutaneously injected into the ear of the mice. After three weeks from the injection, the ear was 
dissected and the outer layer of the skin was directly whole mounted on a glass slide using 99% Glycerol (Sigma) 
and imaged with a Leica SP5 confocal microscope. 1 µg/ml DAPI (Invitrogen # D1306) was used to stain nuclei. 
All images were analysed with ImageJ.
Cas9 in-vitro digestion assay. In-vitro digestion assay was performed as previously described23. Briefly, 
Cas9 protein or CLIP-Cas9 (30 nM) were mixed in-vitro with chemically synthesized Atat1 crRNA and trRNA 
(30 nM) and incubated with Atat1 PCR amplicons (30 ng/μl) at 37 °C for 1 hr in a Cas9 Nuclease Reaction Buffer 
(NEB). After nuclease reaction, mixture was treated with RNase A (5 mg/ml) and further incubated at 37 °C for 
30 minutes to remove RNA. Reactions were stopped with 6× DNA loading buffer containing 30% glycerol, 1.2% 
SDS and 250 mM EDTA, and analyzed by electrophoresis in a 2% agarose gel.
Electroporation of RNP complexes and DNA in primary keratinocytes. Electroporation was carried 
out using the AMAXA Human Keratinocyte NUCLEOFECTOR Kit (Lonza) following the manufacturer’s instruc-
tions. CLIP-Cas9 or Cas9 protein (20 μM) were incubated in-vitro with chemically synthesized Atat1 crRNA (13 μM) 
and trRNA (13 μM) in a final volume of 5 μl at 37 °C for 45 minutes in gentle agitation44. Primary keratinocytes were 
isolated as described above and prior to plating were resuspended in 100 μl of NUCLEOFECTOR solution together 
with CLIP-Cas9 or Cas9 ribonucleoprotein complexes. For DNA electroporation, keratinocytes were resuspended 
in 100 μl of NUCLEOFECTOR solution together with plasmids (2 μg - pPB-U6-Atat1) expressing the sgRNA of 
interest under the U6 promoter45 prior plating. Cells were electroporated selecting the NUCLEOFECTOR program 
T-24 (NUCLEOFECTOR Device I) and transferred immediately into coated μ-Dish 35 mm ibidiTreat dishes (Ibidi) 
or coated 12-well plates. Cells were kept in KSFM in a humidified 37 °C cell incubator with 7% CO2 and media was 
changed every day. After 72–96 hr genomic DNA was isolated to assess genome editing results.
T7 Endonuclease I assay. Genomic DNA was isolated from treated keratinocytes. PCR amplicons containing 
the on-target site from the genomic locus of interest were amplified using described primers (Sigma Aldrich) and 
10× DREAMTAQ Green Buffer (ThermoFisher Scientific), 0.25 mM each dNTP, 0.2 μM each primer and 0.025 
U/μL DREAMTAQ DNA polymerase (ThermoFisher Scientific). The reaction was incubated in a thermal cycler 
programmed for 5 minutes at 95 °C followed by 34 cycles of 98 °C for 30 seconds, 60 °C for 30 seconds and 72 °C for 
30 seconds then a final extension at 72 °C for five minutes. PCR fragments were separated by electrophoresis on a 
2% Agarose gel, extracted from gel (QIAquick Gel Extraction Kit, Qiagen # 28115) and quantified at NANODROP 
ND-8000. 500 ng of each amplicon were diluted to 19 μL with 10× NEB Buffer 2 and water. The amplicon was dena-
tured and rehybridized in a thermal cycler programmed to incubate for 10 minutes at 95 °C for 10 minutes followed by 
1 minute each at 85 °C, 75 °C, 65 °C, 55 °C, 45 °C, 35 °C, and 25 °C with a 2 °C/second ramp rate. 1 μL of T7E1 (10 U/μL) 
(NEB #M0302S) was added and the reactions were incubated at 37 °C for 30 min. Each sample was then analyzed by 
electrophoresis on a 2% agarose gel, stained with Ethidium Bromide, and imaged at CHEMIDOC (Biorad).
TIDE analysis. PCR amplicons of on-target sites were amplified and purified as previously described. Sanger 
traces were generated by Eurofins Genomics and analyzed with the TIDE webtool (http://tide.nki.nl)24. Default 
parameters were used for the analysis.
Primary keratinocyte RNP internalization imaging. Primary keratinocytes were cultured as described 
above. 48 hr after plating, cells were incubated with 2 μM of S-CROSS complexes or CLIP-Cas9 (linker #6) (with 
or without Atat1 crRNA and trRNA) in a final volume of 100 μL of keratinocytes serum free media for 2 hours in 
a humidified 37 °C cell incubator with 7% CO2. After incubation, cells were washed 3 times with PBS-Heparin 
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(1 mg/ml solution) and live imaged with a Leica SP5 confocal microscope. For protamine experiments, 
cross-linked RNP complexes or CLIP-Cas9 (with Atat1 crRNA and trRNA) were mixed in-vitro with an excess of 
native protamine (1:2 molar ratio) in PBS or CIB buffer (pH = 7.4) for 45 minutes at 37 °C. Reactions were diluted 
to 2 μM in a final volume of 100 μL of keratinocytes serum free media and applied to cells for 2 hours in a humid-
ified 37 °C cell incubator with 7% CO2. After incubation cells were washed 3 times with PBS-Heparin (1 mg/ml 
solution) and live imaged with a Leica SP5 confocal microscope. For ppTG21 peptide, cross-linked RNP com-
plexes or CLIP-Cas9 (with or without Atat1 crRNA and trRNA) were mixed in-vitro with an excess of 30 molar 
equivalent of ppTG21 peptide in PBS or CIB buffer (pH 7.4) for 5 min at RT. Successively, reactions were diluted 
to 2 μM in a final volume of 100 μL of keratinocytes serum free media and applied to cells for 2 hours in a humid-
ified 37 °C cell incubator with 7% CO2. After incubation cells were washed 3 times with PBS-Heparin (1 mg/ml 
solution) and live imaged with a Leica SP5 confocal microscope. 1 µg/ml Hoechst was used for nuclear staining.
In-vitro electroporated primary keratinocyte treatment with CLIP-Cas9 S-CROSS. CLIP-Cas9 
cross-linked complexes were diluted in-vitro in keratinocyte serum free media to the desired concentration 
(2 μM) in a final volume of 100 μl. 36 hr after plasmid electroporation, adult primary keratinocytes were incu-
bated with 100 μl of S-CROSS overnight in a humidified 37 °C cell incubator with 7% CO2. After incubation cells 
were washed 3 times with PBS-Heparin (1 mg/ml solution). After 72–96 hr, BFP positive cells were FACS sorted 
and genomic DNA was isolated to assess genome editing results. For ppTG21 peptide treatment, CLIP-Cas9 
cross-linked complexes were mixed in-vitro with an excess of 30 molar equivalent of ppTG21 peptide for 5 min at 
RT prior incubation with cultured keratinocytes.
AAV production. Recombinant AAV1/2 carrying U6-sgRNA sequence targeting the mouse ß-Actin gene 
and the monomeric Green Fluorescent Protein (mEGFP) sequence flanked by 1 kb sequences homologous to 
ß-Actin29 as a cargo was produced in HEK293 cells as described previously46,47. Cells were harvested 5 days post 
infection, lysed with Triton X-100 at 0.5%, nuclease treated, concentrated by tangential flow filtration, and puri-
fied using isopycnic ultracentrifugation48. Vector genome titration was performed using Q-PCR with primers 
targeting the promoter region of the viral cargo46.
In-vitro N2a cell treatment with CLIP-Cas9 S-CROSS. At day 1, N2a cells were plated in a 96-well 
plate at 60–70% confluence and left recovering in a humidified 37 °C cell incubator with 5% CO2. A plasmid 
encoding for TrkA receptor was transfected 8–10 hr after plating using Lipofectamine 2000 Transfection Reagent 
(ThermoFisher Scientific). 24 hr after plating, cells were infected with 1 uL of AAV1/2::HDR in 30 uL of PBS 
and returned to the incubator. 30 minutes after infection, 70 uL of Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco) supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin/Streptomycin (P/S) were added. 
After 8–24 hr, cells were starved for 30 min in serum free media (DMEM). NGFSNAP::CLIPCas9 cross-linked com-
plexes (or CLIP-Cas9) were diluted in-vitro in CIB buffer to the desired concentration (1–2 μM) in a final vol-
ume of 30 μl and immediately applied to starved N2a cells. For ppTG21 peptide co-treatment, NGFSNAP::CLIPCas9 
cross-linked complexes were mixed in-vitro with an excess of 30 molar equivalent of ppTG21 peptide in CIB 
buffer (pH 7.4) for 5 min at RT prior treatment. 30–60 minutes after treatment, 70 uL of DMEM supplemented 
with 10% FBS and 1% P/S were added. Cells were left in a humidified 37 °C cell incubator with 5% CO2 for 2–4 
days (48–96 hr) and live imaged with a Leica SP5 confocal microscope.
In-vivo treatment with CLIP-Cas9 S-CROSS. Cross-linked complexes were diluted in-vitro in CIB buffer 
to the desired concentration (5 μM) together with 5 uL of AAV1/2::HDR in a final volume of 10–15 μl and subcu-
taneously injected into the ear of the mice. For dual AAV treatment, 5 μl of AAV1/2::HDR were mixed with 5 uL of 
AAV1/2::Cas9 and subcutaneously injected into the ear of the mice. After 15–21 days from the injection, the ear was 
dissected and the outer layer of the skin was fixed for 30 minutes in PFA 4%. After fixation, the sample was washed 3 
times with PBS and cleared overnight in a ScaleA2 solution (4 M urea, 10% (wt/vol) glycerol and 0.1% (wt/vol) Triton 
X-100; pH = 7.7)49. The following day the samples were mounted on a glass slide and imaged with a Leica SP5 confo-
cal microscope. 1 µg/ml DAPI (Invitrogen # D1306) was used to stain nuclei. All images were analysed with ImageJ.
SDS-PAGE and western blotting. To assess the coupling reaction, CLIP-Cre or CLIP-Cas9 were coupled 
with an excess of BC-Surface488 or BCTMR at a 1:1.5 molar ratio (NEB #S9232S; #S9219S) for 1 hour at 37 °C in PBS 
(pH 7.4). The coupling reactions were analyzed by SDS-PAGE on a precast acrylamide gel (BioRad #456-9034), 
along with known concentrations of proteins alone. The bands corresponding to the binding were visualized by 
gel fluorescence. To assess the cross-linking reaction, cross-linked samples were analyzed by SDS-PAGE on a 
precast acrylamide gel, alongside a sample of known concentration. Quantification was performed as previously 
described. All the samples were visualized by Coomassie staining.
For SNAP-ligands and cross-linked complexes internalization, keratinocytes were treated for 2 hours at 37 °C, 
washed three times with PBS-Heparin (1 mg/mL) and then collected by scraping in 1 mL of cold PBS. The cell 
suspension was centrifuged and lysed in RIPA Buffer (Sigma, #R0278) with proteases inhibitor cocktail (Roche 
#11873580001). For all the experiments, the total lysate was separated on 10% or 8% SDS-PAGE gel and trans-
ferred to a nitrocellulose membrane (Protran #10600007). Membranes were incubated with anti-SNAP antibody 
(NEB #P9310S) or with anti-ß-actin antibody (Cell Signaling #4970). Bands were visualized using the ECL detec-
tion system (Amersham #RPN2106); band density was calculated using ImageJ.
Flow cytometry. To confirm gene editing at the Atat1 locus, BFP positive primary keratinocytes were iso-
lated for genomic DNA isolation using a BD FACSAria III cell sorter (Becton Dickinson, San Jose, USA). The 
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cells were incubated with EDTA 0.05% solution (in DPBS) for 10–15 minutes at 37 °C and then incubated with 
0.05% trypsin, 0.02% EDTA until detachment. After trypsinization, cells were suspended in FACS buffer (1x PBS; 
10% FBS; 2 mM EDTA) and sorted directly into lysis buffer for DNA extraction with a 100 μm nozzle at 20 PSI 
and sorting mask values of yield = 0, purity = 32, and phase = 0. Physical parameters were measured by FSC and 
SSC from a 488 nm 100 mW laser and BFP was excited by a 405 nm 100 mW laser and detected through a 450/50 
band-pass filter. To select the BFP expressing population to be sorted, the following gating scheme was used: an 
initial viability gate of SSC-A vs. FSC-A, then down selection by 2 coincidence gates of FSC-W vs FSC-H and 
SSC-W vs SSC-H, followed by a BFP positive inclusive gate from an SSC-A vs BFP dot plot. Untreated primary 
keratinocytes were used to determine the non-BFP keratinocytes so that BFP positive cells could be gated.
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